2 results
Approved WMOCompleted
Primary• To assess the effects of RVT-101 versus placebo on global function as measured by the Clinician*s Interview-Based Impression of Change Plus Caregiver Input (CIBIC+) after 24 weeks of treatment• To assess the effects of RVT-101 versus…
Approved WMOCompleted
Part A1(KIN-2787 Monotherapy Escalation):Determine safety and tolerability of PO administration of Kin-2787 including DLT in participants with BRAFmutation-positive advanced or metastatic solid tumors or melanoma harboring NRAS-mutation. Identify…